Document is current
Any future updates will be listed below
-
Authors
Wolthuis, David F. G. J. https://orcid.org/0000-0002-2152-4490
Freriksen, Jolien J. M.
ter Avest, Mendy
Kartha, Reena V.
de Wildt, Saskia N.
Wijnsma, Kioa
van de Kar, Nicole C. A. J.
ter Heine, Rob
- License Information
-
More Information
Article History
Received: 3 December 2024
Revised: 2 January 2025
Accepted: 2 January 2025
First Online: 3 February 2025
Declarations
:
: This study does not involve the use of real patient data. Instead, it utilizes randomly generated patient data to simulate clinical scenarios. The creation and use of these randomly generated datasets were conducted in accordance with ethical research guidelines, ensuring that no actual patient information was utilized. As the study does not involve human participants or identifiable data, ethical approval from an institutional review board (IRB) or ethics committee was not required. However, all procedures followed applicable ethical standards for the use of simulated data in research.
: Nicole van der Kar has no conflicts of interest related to this study, but is the chair of the Thrombotic Microangiopathy Working Group of ERKnet (unpaid) and the chair of the International Steering Committee symposia on Verocytotoxin-Producing E. coli Infections (unpaid). She also receives consulting fees from Roche and Alexion (to institution), payment for lectures from Sobi (to institution), and fees for expert testimony from Samsung (to institution). Reena V. Kartha has received investigator-initiated grants from Sanofi, Pfizer Inc., and Takeda Pharmaceuticals for research in Gaucher disease, and receives consulting fees from Gain Therapeutics, payment for lectures from Saterdalen & Associates LLC, and support for attending meetings from Saterdalen & Associates LLC. She is also a member of several advisory boards and boards related to rare diseases. Saskia N. de Wildt has received research grants from EU IMI2, Roche (investigator-initiated research grant), and the Bill & Melinda Gates Foundation. She also receives payment for expert testimony from Erasmus MC University Medical Center (to institution), and holds a pending patent for the use of PENK as an AKI marker in children. She is also involved in several non-commercial and commercial foundations and organizations.
